Cost effectiveness and quality of life analysis of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest.


Journal

Resuscitation
ISSN: 1873-1570
Titre abrégé: Resuscitation
Pays: Ireland
ID NLM: 0332173

Informations de publication

Date de publication:
06 2019
Historique:
received: 03 01 2019
revised: 20 02 2019
accepted: 14 03 2019
pubmed: 30 3 2019
medline: 4 8 2020
entrez: 30 3 2019
Statut: ppublish

Résumé

The use of extracorporeal membrane oxygenation (ECMO) in refractory cardiac arrest (ECPR) has increased exponentially. ECPR is a resource intensive service and its cost effectiveness has yet to be demonstrated. We sought to complete a cost analysis with modelling of cost effectiveness and quality of life outcomes. We sought to complete a cost analysis with modelling of cost effectiveness and quality of life outcomes of patients who have undergone ECPR. Using data on all extracorporeal cardiopulmonary resuscitation (ECPR) patients at two ECMO centres in Sydney, Australia; we completed a costing analysis of ECPR patients. A Markov model of cost, quality of life and survival outcomes was developed to examine cost per QALY estimates and incremental cost effectiveness ratios (ICERs). Probabilistic sensitivity analysis (PSA) was completed to assess the probability of cost effectiveness for base case and variations. Sixty-two consecutive ECPR patients were analysed; mean age of 51.9 ± 13.6 years, 38 (61%) were in hospital cardiac arrests (IHCA). Twenty-five patients (40%) survived to hospital discharge; all with a cerebral performance category (CPC) of 1 or 2. The mean cost per ECPR patient was AUD 75,165 (€50,535; ±AUD 75,737). Over 10 years ECPR was estimated to add a mean gain of 3.0 Quality Adjusted Life Years (QALYs) per patient with an incremental cost effectiveness ratio (ICER) of AUD 25,212 (€16,890) per QALY, increasing to 4.0 QALYs and an ICER of AUD 18,829 (€12,614) over a 15-year survival scenario. Mean cost per QALY did not differ significantly by OHCA or IHCA. ECMO support for refractory cardiac arrests is cost effective and compares favourably to accepted cost effectiveness thresholds.

Sections du résumé

BACKGROUND
The use of extracorporeal membrane oxygenation (ECMO) in refractory cardiac arrest (ECPR) has increased exponentially. ECPR is a resource intensive service and its cost effectiveness has yet to be demonstrated. We sought to complete a cost analysis with modelling of cost effectiveness and quality of life outcomes. We sought to complete a cost analysis with modelling of cost effectiveness and quality of life outcomes of patients who have undergone ECPR.
METHODS
Using data on all extracorporeal cardiopulmonary resuscitation (ECPR) patients at two ECMO centres in Sydney, Australia; we completed a costing analysis of ECPR patients. A Markov model of cost, quality of life and survival outcomes was developed to examine cost per QALY estimates and incremental cost effectiveness ratios (ICERs). Probabilistic sensitivity analysis (PSA) was completed to assess the probability of cost effectiveness for base case and variations.
RESULTS
Sixty-two consecutive ECPR patients were analysed; mean age of 51.9 ± 13.6 years, 38 (61%) were in hospital cardiac arrests (IHCA). Twenty-five patients (40%) survived to hospital discharge; all with a cerebral performance category (CPC) of 1 or 2. The mean cost per ECPR patient was AUD 75,165 (€50,535; ±AUD 75,737). Over 10 years ECPR was estimated to add a mean gain of 3.0 Quality Adjusted Life Years (QALYs) per patient with an incremental cost effectiveness ratio (ICER) of AUD 25,212 (€16,890) per QALY, increasing to 4.0 QALYs and an ICER of AUD 18,829 (€12,614) over a 15-year survival scenario. Mean cost per QALY did not differ significantly by OHCA or IHCA.
CONCLUSIONS
ECMO support for refractory cardiac arrests is cost effective and compares favourably to accepted cost effectiveness thresholds.

Identifiants

pubmed: 30922936
pii: S0300-9572(19)30089-9
doi: 10.1016/j.resuscitation.2019.03.021
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-56

Informations de copyright

Crown Copyright © 2019. Published by Elsevier B.V. All rights reserved.

Auteurs

Mark Dennis (M)

Sydney Medical School, University of Sydney, Sydney, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. Electronic address: mark.dennis@sydney.edu.au.

Fredrick Zmudzki (F)

Époque Consulting, Sydney, Australia; Social Policy Research Centre, University of New South Wales, Sydney, Australia. Electronic address: fzmudzki@epoqueconsulting.com.au.

Brian Burns (B)

Sydney Medical School, University of Sydney, Sydney, Australia; Greater Sydney Area HEMS, NSW Ambulance Service, Australia. Electronic address: brian.burns@sydney.edu.au.

Sean Scott (S)

Department of Emergency Medicine, St. Vincent's Hospital, Sydney, Australia. Electronic address: sean.scott@svha.org.au.

David Gattas (D)

Sydney Medical School, University of Sydney, Sydney, Australia; Department of Intensive Care, Royal Prince Alfred Hospital, Sydney, Australia. Electronic address: david.gattas@health.nsw.gov.au.

Claire Reynolds (C)

Department of Intensive Care, Centre for Applied Medical Research, St. Vincent's Hospital, Sydney, Australia. Electronic address: claire.reynolds@svha.org.au.

Hergen Buscher (H)

Department of Intensive Care, Centre for Applied Medical Research, St. Vincent's Hospital, Sydney, Australia; University of New South Wales, Sydney, Australia. Electronic address: hergen.buscher@svha.org.au.

Paul Forrest (P)

Sydney Medical School, University of Sydney, Sydney, Australia; Department of Anaesthesia, Royal Prince Alfred Hospital, Sydney, Australia. Electronic address: paul.forrest@health.nsw.gov.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH